[2021] Blood Clotting Accelerant Market – Size Estimation, Share, Upcoming Trends, Growth, Medical Technology, Future Scenario, Contribution of Top Leading Players 2027

SEATTLE, April 14, 2021, (PHARMIWEB) — Overview:

Blood clotting accelerants help improve blood clotting in the treatment of anaemia, hemophilia, deep vein thrombosis, pulmonary embolism, and hereditary blood deficiencies. These accelerants are accessible in two types, crystalline blood clot accelerants and aqueous blood clot accelerants, while crystalline blood clot accelerants are more successful over aqueous blood clot accelerants because of its more extended time span of usability period.

To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/4245

Covid-19 impact:

Use of blood clot accelerants may increase the risk of Covid-19 infection in patients suffering from thrombosis, blood cancer, and pulmonary embolism.

Drivers:

High prevalence of deep vein thrombosis is expected to propel growth of the blood clotting accelerant market. For instance, according to the Centers for Disease Control and Prevention (CDC), from 1998 to 2014, around 900,000 people suffer from deep vein thrombosis (DVT)/ pulmonary embolism each year in the U.S.

Moreover, R&D of new therapies is also expected to aid in growth of the market. For instance, in July 2020, Precision Biologic Inc, a leading developer of blood clot accelerant products, announced the launch of CYROCHECK chromogenic factor VIII assay in the U.S. It will be used by clinical labs for determination of factor VIII in human plasma in case of hemophilia A. Similarly, in 2019, Octapharma AG, announced that the human fibrinogen concentrate FIBRYGA received approval for use in treatment of acquired fibrinogen deficiency (AFD) in 15 European countries

Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4245

Restraints:

The difficulty in handling the blood clot accelerants in expected to hinder growth of blood clotting accelerants market. Small mistake in handling the equipment may lead to severe conditions in patients.

Market Taxonomy:

The global blood clotting market by product form, is segmented into:

• Powder
• Solution
• Others
• By Route of Administration:
  • Topical
  • Parental

• By End User:
  • Speciality Clinics
  • Hospitals
  • Research Institutes
  • Diagnostic Laboratories

• By Region:
  • North America
  • Latent America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa

Regional Analysis:

North America is expected to witness significant growth in blood clotting accelerant market in the forecast. This can be attributed to various R&D activities. For instance, in 2019, Baxter International Inc announced that it received the U.S. Food and Drug Administration (FDA) approval for faster preparation of its leading hemostatic product, Floseal Hemostatic Matrix, which helps to stop bleeding 96% of the time within 10 minutes during surgical procedures.

Similarly, in 2019, Grifols, S.A. and Johnson & Johnson announced that it received approval from the U.S. Food Drug and Administration to market VISTASEAL. Vistaseal is a fibrin sealant used to manage surgical bleeding.

Moreover, Europe is also expected to witness significant growth in blood clotting accelerant market. The growth in the market is attributed to increasing prevalence of blood related diseases such as thrombosis, blood cancer, and pulmonary embolism. For instance, in June 2020, Kedrion Biopharma supported ‘WFH Virtual Summit 2020’ the summit had presence of international experts present to discuss on opportunity on most current and relevant topic in field of coagulation disorders, including the challenges faced by pharmaceutical companies in COVID-19 pandemic.

Competitive Section:

The major players involved in global blood clotting accelerant market are Novo Nordisk A/S, Sekisui Chemical CO. LTD, CSL Limited, Baxter International Inc, PeproTech Inc, and Kedrion SpA. Kedrion S.P.A, Octapharma AG, Greiner Bio-One AG, Grifols International SA, and ACROBiosystems.

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837